Day One Biopharmaceuticals, Inc. ( (DAWN) ) has released its Q3 earnings. Here is a breakdown of the information Day One Biopharmaceuticals, Inc. presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Day One Biopharmaceuticals, Inc., based in Brisbane, California, is a biopharmaceutical company focused on developing and commercializing targeted therapies for life-threatening diseases across all age groups. In its latest earnings report, Day One Biopharmaceuticals highlighted significant growth in its core business, particularly with its product OJEMDA, and raised its full-year 2025 revenue guidance. The company reported a 15% increase in OJEMDA net product revenue in the third quarter of 2025 compared to the previous quarter, with year-to-date revenue showing an 89% increase over the previous year. Additionally, new patient starts and prescriptions have seen substantial growth, driven by clinical trial data. Financially, Day One ended the third quarter with $451.6 million in cash and investments, despite a net loss of $19.7 million for the quarter. Looking ahead, Day One Biopharmaceuticals is optimistic about its growth prospects, supported by ongoing clinical trials and strategic advancements in its pipeline.